Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
FDA Office of Orphan Products Development |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
ClinicalTrials.gov Identifier: | NCT00761228 |
The purpose of this study is to test the drug apomorphine in subjects who are in a Vegetative State or a Minimally Conscious State.
Condition | Intervention | Phase |
---|---|---|
Brain Injury |
Drug: Apomorphine Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of NH001 in Improving the Functional Outcome of Patients in a Vegetative State or Minimally Conscious State Following a Severe Traumatic Brain Injury |
Estimated Enrollment: | 76 |
Study Start Date: | November 2008 |
Estimated Study Completion Date: | October 2010 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Apomorphine: Active Comparator
Patients will receive an ascending dosing schedule to reach a maximum infusion rate of 6 mg/hour for 12 hours a day.
|
Drug: Apomorphine
Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of 6 mg/hour for 12 hours a day.
|
Placebo: Placebo Comparator
Patients will receive a continues subcutaneous infusion of saline solution.
|
Drug: Placebo
Patients will receive a continues subcutaneous infusion of saline solution.
|
This is a prospective, multi-center, randomized, double-blind, placebo-controlled study of the safety and efficacy of NH001 to improve the functional outcome of patients in a vegetative state or minimally conscious state following a severe TBI.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Daniel Katzman | 617.331.4111 | daniel@neurohealing.com |
United States, Massachusetts | |
Spaulding Rehabilitation Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Elkan R Gamzu, PhD | NeuroHealing Pharmaceuticals Inc. |
Principal Investigator: | Ross D Zafonte, DO | Spaulding Rehabilitation Hospital |
Responsible Party: | NeuroHealing Pharmaceuticals ( Elkan Gamzu, Interim Head of Clinical Trials ) |
Study ID Numbers: | 3337 |
Study First Received: | September 26, 2008 |
Last Updated: | September 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00761228 |
Health Authority: | United States: Food and Drug Administration |
Vegetative State Minimally Conscious State Coma Traumatic Brain Injury |
Unconsciousness Vegetative State secondary to a Traumatic Brain Injury Minimally Conscious State secondary to a Traumatic Brain Injury |
Persistent Vegetative State Craniocerebral Trauma Unconsciousness Brain Damage, Chronic Consciousness Disorders Wounds and Injuries Central Nervous System Diseases Disorders of Environmental Origin Trauma, Nervous System |
Brain Diseases Apomorphine Coma Signs and Symptoms Dopamine Neoplasm Metastasis Neurologic Manifestations Brain Injuries Neurobehavioral Manifestations |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases |
Antiparkinson Agents Dopamine Agents Dopamine Agonists Central Nervous System Agents Pharmacologic Actions |